Clinical Trials

366 enrolled

Breast Neoplasms

NCT05065021 2024-01-17

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

40 enrolled

Phase EARLY_PHASE1 Unknown

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06208033 2024-01-17

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

40 enrolled

Phase EARLY_PHASE1 Unknown

EGFR Positive Non-small Cell Lung Cancer

NCT06204614 2024-01-12

Drug Screening Using IMD in Bladder Cancer

18 enrolled

Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

NCT06197438 2024-01-09

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

36 enrolled

Stomach Neoplasms

NCT02037048 2024-01-08

FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma

63 enrolled

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT04714190 2023-12-21

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

351 enrolled

Stomach Neoplasms

NCT03935256 2023-12-18

Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer

24 enrolled

Neoplasms, Endometrial Neoplasms

NCT05262335 2023-11-28

ALTER-G-001

116 enrolled

Digestive System Neoplasms

NCT00997009 2023-11-14

MITO CERV 2

108 enrolled

Uterine Cervical Neoplasms

NCT04308837 2023-11-14

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

29 enrolled

Stomach Neoplasms

NCT03503786 2023-11-13

MITO END-3

125 enrolled

Endometrial Neoplasms

NCT02584478 2023-11-08

AL3818

294 enrolled

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04938583 2023-10-17

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Phase 1/2 Unknown

54 enrolled

Ovarian Neoplasms

NCT00411138 2023-10-11

PORTEC-3

670 enrolled

Endometrial Neoplasms

NCT05783921 2023-07-28

A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Unknown

60 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05966441 2023-07-28

Role of Curcumin in Paclitaxel Induced PN

80 enrolled

Breast Neoplasms

NCT05603065 2023-06-29

TINES

Phase 4 Unknown

32 enrolled

Esophageal Squamous Cell Carcinoma

NCT04201561 2023-06-26

SELENIUM

68 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peripheral Nervous System Diseases

NCT02560298 2023-06-22

InterAACT

91 enrolled

Anal Canal Carcinoma, Anus Neoplasms

NCT05751265 2023-06-22

Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer

39 enrolled

Stomach Neoplasms

NCT05900921 2023-06-13

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

132 enrolled

Advanced Squamous Non-Small-Cell Lung Cancer

NCT05872412 2023-05-25

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

82 enrolled

Triple Negative Breast Neoplasms

NCT03094884 2023-05-23

Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer

Phase 1 Unknown

40 enrolled

GastrointestinalThoracic

Esophageal Neoplasms, Lung Neoplasms

NCT05853172 2023-05-10

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

Stomach Neoplasms

NCT03991403 2023-04-03

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

228 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00326456 2023-03-27

MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer

820 enrolled

Ovarian Neoplasms

NCT00660842 2023-03-24

MITO-7

800 enrolled

Ovarian Neoplasms, Neurotoxicity Syndromes

NCT01706120 2023-03-24

MITO16/MANGO-2

Phase 4 Unknown

400 enrolled

Ovarian Neoplasms

NCT01802749 2023-03-24

MITO16MANGO2b

406 enrolled

Ovarian Neoplasms

NCT03410784 2023-03-24

MITO28MaNGOov4

72 enrolled

Ovarian Neoplasms

NCT05541146 2023-03-23

Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis

GastrointestinalGynecologic

Carcinoma, Peritoneal Neoplasms, Stomach Neoplasms

NCT04638582 2023-03-22

Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

44 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05753865 2023-03-03

A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

454 enrolled

Advanced Breast Cancer

NCT05749016 2023-03-01

Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer

Locally Advanced Breast Cancer

NCT05749575 2023-03-01

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

28 enrolled

Breast Neoplasms

NCT05741021 2023-02-24

A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

84 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05730777 2023-02-16

Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics

Phase 4 Unknown

200 enrolled

Cancer Therapy-related Cardiovascular Toxicity

NCT03321188 2023-02-06

Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients

20 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04248998 2023-01-18

BREAKFAST

Triple Negative Breast Neoplasms

NCT05681728 2023-01-12

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

26 enrolled

Breast Neoplasms

NCT05214976 2022-12-22

A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

64 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT05446883 2022-11-30

QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

498 enrolled

Uterine Cervical Neoplasms

NCT05627414 2022-11-25

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Stomach Neoplasms

NCT05574998 2022-10-12

FTANLCNDG

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00997906 2022-09-29

Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC

Phase 2/3 Unknown

172 enrolled

Head & Neck

Head and Neck Neoplasms

NCT05552807 2022-09-23

SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1 Unknown

120 enrolled

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT05522894 2022-08-31

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

80 enrolled